Division of Takeda Pharmaceutical Co. Ltd.
Latest From Premacure AB
The biotech laid out its pipeline during a Dec. 10 R&D day in hopes of convincing analysts and investors that its rare disease focus will pay off in coming years.
The specialty pharma has worked with regulators to determine a next step for its late-stage eye drug and intends to build a business unit around the compound.
Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.
Shire has agreed to pay $4.2bn to acquire ViroPharma, which sells the orphan drug Cinryze. The prophylactic treatment is for the rare disease hereditary angioedema (HAE).
- Large Molecule
- Therapeutic Areas
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
- Jan Borg, CEO
- Contact Info
Phone: 70 650 28 52
Uppsala Science Park
Uppsala, SE-751 83
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.